Kymera Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$138.00

+1.28%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:11 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $136.25
Volume: 127
Day's high: —
Day's low: —

In brief

Kymera Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $11.78B.
Its shares closed at $136.25 on 4 Nov 2026, up 127.4% over the past year.
From India you can buy KYMR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Kymera Therapeutics, Inc. (KYMR) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole KYMR share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade KYMR options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 4 Nov 2026
Closed at $136.25 on 4 Nov 2026: 0.2% below the 52-week high of $136.57 (4 Nov 2026) and 140.1% above the low of $56.75 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +28.6% (SPY −1.6%, XLV +13.5%). 3 months: +29.2% (SPY −0.4%, XLV +15.5%). 1 year: +127.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KYMR, SPY and XLV · as of 4 Nov 2026
10.0 days to cover short interest
9.2M shares were sold short at the 15 Oct 2026 settlement, 10.7% of the 85.4M shares outstanding; covering them would take 10.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $136.25 was 18.1% above its 50-day average ($115.38) and 40.0% above its 200-day average ($97.33). It has closed above the 200-day for 311 sessions, since 12 Aug 2025. The 50-day average crossed above the 200-day on 14 Jul 2025, 331 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 76.7, 70 or above
The 14-session relative strength index closed at 76.7 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+28.6%

6 months+58.0%

1 year+127.4%

5 years+109.6%

Newswire

About

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Website

Notable moves

December 8, 2025
+41.55%
June 2, 2025
+45.51%
May 3, 2022
−23.98%

Kymera Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$138.00

+1.28%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:11 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $136.25
Volume: 127
Day's high: —
Day's low: —

In brief

Kymera Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $11.78B.
Its shares closed at $136.25 on 4 Nov 2026, up 127.4% over the past year.
From India you can buy KYMR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Kymera Therapeutics, Inc. (KYMR) shares from India?

Do I need the price of a whole KYMR share to invest?

How much can I invest in US stocks in a year?

Can I trade KYMR options or futures?

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 4 Nov 2026
Closed at $136.25 on 4 Nov 2026: 0.2% below the 52-week high of $136.57 (4 Nov 2026) and 140.1% above the low of $56.75 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +28.6% (SPY −1.6%, XLV +13.5%). 3 months: +29.2% (SPY −0.4%, XLV +15.5%). 1 year: +127.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KYMR, SPY and XLV · as of 4 Nov 2026
10.0 days to cover short interest
9.2M shares were sold short at the 15 Oct 2026 settlement, 10.7% of the 85.4M shares outstanding; covering them would take 10.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $136.25 was 18.1% above its 50-day average ($115.38) and 40.0% above its 200-day average ($97.33). It has closed above the 200-day for 311 sessions, since 12 Aug 2025. The 50-day average crossed above the 200-day on 14 Jul 2025, 331 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 76.7, 70 or above
The 14-session relative strength index closed at 76.7 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+28.6%

6 months+58.0%

1 year+127.4%

5 years+109.6%

Newswire

About

Website

Notable moves

December 8, 2025
+41.55%
June 2, 2025
+45.51%
May 3, 2022
−23.98%

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. in brief

Set a 52-week high on 4 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

10.0 days to cover short interest

Above its 50- and 200-day averages

RSI(14) at 76.7, 70 or above

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. in brief

Set a 52-week high on 4 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

10.0 days to cover short interest

Above its 50- and 200-day averages

RSI(14) at 76.7, 70 or above